All In Biotech

Drug Trial Radar · NCT00949624

CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors

Phase I Study To Determine The Maximally Tolerated Dose Of Oral, Daily CP-868,596 And CP-868,596 Plus AG-013736 When Given In Combination With Docetaxel Administered Every 3 Weeks To Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 19, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

Dec 2005

Primary completion

Jun 2008

Study completion Jun 2008

Sponsor

Lead sponsor
Arog Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jul 30, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A5301005 is a phase 1 study in patients with solid tumors which is testing the safety and tolerability of adding targeted agents to a standard chemotherapy. CP-868,596 is a platelet-derived growth factor receptor inhibitor (PDGFR) and AG-13736 is a vascular endothelial growth factor receptor inhibitor (VEGFR). This study will test the use of docetaxel (the standard chemotherapy) with either CP-868,596 or the combination of CP-868,596 and AG-13736.

Conditions

  • Advanced Solid Tumors

Interventions

  • CP-868,596Drug

    Oral tablet 60 mg BID continuous

  • DocetaxelDrug

    Intravenous 75 mg/m2 every three weeks

  • CP-868,596Drug

    Oral tablet 100 mg BID continuous

  • DocetaxelDrug

    Intravenous 75 mg/m2 every three weeks

  • CP-868,596Drug

    Oral tablet 100 mg BID continuous

  • DocetaxelDrug

    Intravenous 100 mg/m2 every three weeks

  • CP-868,596Drug

    Oral tablet 60 mg BID continuous

  • AG-013736Drug

    Oral tablet 5 mg BID continuous

  • DocetaxelDrug

    Intravenous 75 mg/m2 every three weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. First-cycle Dose Limiting ToxicitiesTime frame: 2.5 years

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Durham, North Carolina

  • Pfizer Investigational Site

    East Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.